This gap emphasizes the critical need for integrated, multidisciplinary, and sustainable care strategies to support long-term behavioral change ( The presence of complex comorbidities in a subset of participantssuch as syndromic or hypothalamic obesity, neurodevelopmental disorders, and chronic systemic diseasesmay influence therapeutic responsiveness, potentially attenuating the magnitude of treatment effects
Clinical Evidence Pivotal Studies and Randomized Controlled Trial Evidence Description of Studies Study 023 was a phase III, open-label trial with a 14-week, randomized, double-blind, placebo-controlled period followed by a 52-week, open-label period that aimed to evaluate the efficacy and safety of setmelanotide (1 mg to 3 mg daily by subcutaneous [SC] injection) in patients aged greater than or equal to 6 years with BBS or Alstrm syndrome (AS) and obesity
GLP-1 medications work by reducing appetite and blood sugar, and fatigue during this transition does not indicate that weight loss or metabolic benefits are not occurring
For me shes a role model not just as a professional, but I also admire her as a strong woman
&srotate=0)
